Releasing GM Mosquitoes in Burkina Faso is Dangerous

/in

Releasing GM Mosquitoes in Burkina Faso is Dangerous

Tags: , ,
Irina Vekcha,  Countercurrents,  2025.

The Target Malaria project claims to be able to eradicate malaria by using gene drive technology to eliminate Anopheles mosquitoes, the malaria vectors. There are several gene drive projects around the world, targeting different species (insects, mammals, fungi, etc.), using different types of gene drives, and having different stages of the technology readiness. The details of these projects are provided in the Table 2 of the Gene Drives report, produced by ENSSER, the European Network of Scientists for Social and Environmental Responsibility. The Target Malaria project, using the CRISPR/Cas9 system for the Anopheles gambiae elimination, is the most advanced project. The project was conceived in Great Britain, at Imperial College London, in the laboratory led by Andrea Crisanti. The project experimental protocol is very complex: it comprises three phases, each phase focusing on a particular type (strain) of GM mosquitoes. Only the third phase is aiming to fight against malaria, and only this phase is based on the use of the gene drive technology. All the strains are produced by Crisanti’s team and must be imported to Burkina Faso for field trials. After importation, the mosquitoes are managed by the local Target Malaria team led by Abdoulaye Diabate; each phase should normally end with mosquito release by Diabate’s team.

The project is moving forward rapidly, thanks to huge capital injections, coming primarily from the Bill Gates Foundation. The project is strongly supported by the NEPAD, New Partnership for Africa’s Development, an African Union agency. The NEPAD, which favors gene drives, has appointed ABNE, the African Biosafety Network of Expertise, to oversee Target Malaria experiment. The ABNE is funded by the Bill Gates Foundation, and the NEPAD  – by the Open Philanthropy Project, one of Target Malaria’s funding sources. In 2019, within the framework of the first project phase, Target Malaria released 6,400 GM mosquitoes in the Bana village of the Burkina Faso, despite the Burkinabe civil society protests. The project is currently in its second phase, which began in March 2022, following the importation of the second-phase strain into Burkina Faso. Normally, before importing a strain for field trials, the Crisanti team conducts numerous tests to ensure the strain’s quality, and only the strain that meets all the criteria defined by the experimenter is accepted for importation. However, the project has encountered setbacks.